Apellis Pharmaceuticals, Inc. has reported a first-quarter 2022 loss per share of $1.42, an improvement from $2.32 the previous year, along with revenues of $14.4 million that surpassed expectations. However, the company is dealing with a troubling net cash outflow of $522 million and an overall accounting loss of $702 million, raising concerns about its financial stability amid significant liabilities. On a positive note, Apellis is advancing its drug development efforts with the submission of a New Drug Application for pegcetacoplan, reinforcing its position in innovative therapies.
“Apellis Pharmaceuticals, Inc. · has reported · first-quarter 2022 loss per share · $1.42”
“Apellis Pharmaceuticals, Inc. · has reported · loss per share in the year-ago quarter · $2.32”
“Apellis Pharmaceuticals, Inc. · has reported · total revenues · $14.4 million”
“Apellis Pharmaceuticals, Inc. · has reported · Zacks Consensus Estimate for revenues · $13 million”
“Apellis Pharmaceuticals, Inc. · had cash, cash equivalents and marketable securities worth · as of Mar 31, 2022 · $965.3 million”
“Apellis Pharmaceuticals, Inc. · had cash, cash equivalents and marketable securities worth · as of Dec 31, 2021 · $700.6 million”
“Apellis Pharmaceuticals · had · debt · US$189.2m”
“Apellis Pharmaceuticals · had · cash · US$965.3m”
“Apellis Pharmaceuticals · has · net cash · US$776.1m”
“Apellis Pharmaceuticals · had liabilities · due within 12 months · US$124.8m”
“Apellis Pharmaceuticals · had liabilities · due beyond 12 months · US$558.9m”
“Apellis Pharmaceuticals · had liquid assets · more than total liabilities · US$358.0m”